RG100204 significantly reduced cardiac dysfunction even when administered 3 hours after the onset of sepsis, highlighting AQP9 as a promising drug target for the treatment of sepsis-induced cardiac dysfunction (55). The gene discussed is AQP9; the disease is Sepsis.